T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection

T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection Emerging Microbes &Infections 6, e46 (June 2017). doi:10.1038/emi.2017.31 Authors: Christopher L Cooper, Karen A Martins, Sabrina M Stronsky, David P Langan, Jesse Steffens, Sean Van Tongeren &Sina Bavari
Source: Emerging Microbes and Infections - Category: Infectious Diseases Authors: Tags: adjuvant Ebola germinal center B-cell T-cell dependent antibody vaccine virus-like particle Source Type: research

Related Links:

Cases of a novel pneumonia-like illness that originated in Wuhan, China in December have now been confirmed in South Korea, Thailand, Japan, Taiwan, Macau—and, as of Jan. 21, the U.S. The virus’ geographic reach, as well as its newly discovered ability to spread via person-to-person contact, has health officials worried about the prospect of globals spread. As health officials scramble to learn more about the virus and is origins, researchers are simultaneously turning to the question of how to develop a vaccine or therapy that could help contain transmission worldwide—a feat that experts say is technical...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
In conclusion, the vaccine was locally and systemically well‐tolerated and the viral vector was partially or totally cleared from the organs where it disseminated, supporting the clinical development of the vaccine.
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
Dalhousie University professor Matthew Herder accessed hundreds of government documents to find out what really happened as Canadian scientists tried for years to get the pharmaceutical industry interested in their discovery of an Ebola vaccine.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
Condition:   Ebola Interventions:   Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo Sponsor:   Janssen Vaccines & Prevention B.V. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: National Institutes of Health (NIH). Published: 1/14/2020. This one-hour, 44-minute presentation discusses how the National Institutes of Health (NIH) has been at the forefront in the global effort to prevent the spread of Ebola virus. NIH staff were deployed in western Africa during the 2015-2016 Ebola outbreak to provide primary care to those infected, and Ebola patients were received at the NIH Clinical Center. For many years prior, NIH scientists studied the natural reservoirs of emerging viruses such as Ebola virus and have elucidated the biology of Ebola virus infection, which has informed the creation of in...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
Abstract At the time of writing in 2019, there have been 754 confirmed cases of Lassa fever in Nigeria, 21% of whom have died. Lassa is on the priority pathogen list for WHO's R&D Blueprint for Action to Prevent Epidemics. In September 2019, WHO convened 67 scientists, regulators, ethicists, public health officials, funders and vaccine developers to discuss the end-to-end clinical development plan for Lassa fever vaccines. The substantial increases in vaccine trial capacity in Africa were reviewed, together with lessons learned from the evaluation of vaccines against HIV, TB, malaria, and Ebola in Africa. Particip...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
(INSERM (Institut national de la sant é et de la recherche m é dicale)) Public health efforts successfully stopped human-to-human transmission of Ebola virus in West Africa in 2016 after the worst Ebola outbreak in history. Pursuing and intensifying efforts to develop a safe and effective vaccination strategy against Ebola virus disease, with durable protection in all populations, including children, is vital.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Publication date: Available online 10 January 2020Source: Antiviral ResearchAuthor(s): Elizabeth C. Clarke, Steven B. BradfuteAbstractFor more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these “mouse models” has led to their extensive use in bi...
Source: Antiviral Therapy - Category: Virology Source Type: research
Abstract For more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these "mouse models" has led to their extensive use in biocontainment laboratories to assess the efficacy of novel vaccines, often without consideration of whether adaptive im...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research
[Deutsche Welle] The deadly virus has killed nearly three times as many people in the Democratic Republic of Congo as any Ebola outbreak. It's preventable with a vaccine.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
More News: Ebola | Ebola Vaccine | Vaccines